161 related articles for article (PubMed ID: 29593410)
1. Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy.
Belwal VK; Singh KP
Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):125-127. PubMed ID: 29593410
[TBL] [Abstract][Full Text] [Related]
2. Development of a stable single-vial liposomal formulation for vincristine.
Mao W; Wu F; Lee RJ; Lu W; Wang J
Int J Nanomedicine; 2019; 14():4461-4474. PubMed ID: 31296986
[No Abstract] [Full Text] [Related]
3. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
[TBL] [Abstract][Full Text] [Related]
4. Supramolecular core-shell nanosilica@liposome nanocapsules for drug delivery.
Liu M; Gan L; Chen L; Xu Z; Zhu D; Hao Z; Chen L
Langmuir; 2012 Jul; 28(29):10725-32. PubMed ID: 22746205
[TBL] [Abstract][Full Text] [Related]
5. Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.
Butler KS; Durfee PN; Theron C; Ashley CE; Carnes EC; Brinker CJ
Small; 2016 Apr; 12(16):2173-85. PubMed ID: 26780591
[TBL] [Abstract][Full Text] [Related]
6. The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate.
Zhang J; Chen Y; Li X; Liang X; Luo X
Int J Nanomedicine; 2016; 11():4187-97. PubMed ID: 27616886
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
9. Liposome-mesoporous silica nanoparticles fused cores: a safer mode of drug carrier.
Singh KP; Panwar P; Kohli P; Sanjesh
J Biomed Nanotechnol; 2011 Feb; 7(1):60-2. PubMed ID: 21485803
[TBL] [Abstract][Full Text] [Related]
10. Macromolecularly Crowded Protocells from Reversibly Shrinking Monodisperse Liposomes.
Deng NN; Vibhute MA; Zheng L; Zhao H; Yelleswarapu M; Huck WTS
J Am Chem Soc; 2018 Jun; 140(24):7399-7402. PubMed ID: 29870243
[TBL] [Abstract][Full Text] [Related]
11. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
12. Rapid scale-up and production of active-loaded PEGylated liposomes.
Roces CB; Port EC; Daskalakis NN; Watts JA; Aylott JW; Halbert GW; Perrie Y
Int J Pharm; 2020 Aug; 586():119566. PubMed ID: 32622812
[TBL] [Abstract][Full Text] [Related]
13. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
14. Targeted killing of cancer cells in vivo and in vitro with IGF-IR antibody-directed carbon nanohorns based drug delivery.
Li N; Zhao Q; Shu C; Ma X; Li R; Shen H; Zhong W
Int J Pharm; 2015 Jan; 478(2):644-54. PubMed ID: 25510600
[TBL] [Abstract][Full Text] [Related]
15. Are PEGylated liposomes better than conventional liposomes? A special case for vincristine.
Wang X; Song Y; Su Y; Tian Q; Li B; Quan J; Deng Y
Drug Deliv; 2016 May; 23(4):1092-100. PubMed ID: 26024386
[TBL] [Abstract][Full Text] [Related]
16. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
[TBL] [Abstract][Full Text] [Related]
17. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery.
Chen J; Li S; Shen Q
Eur J Pharm Sci; 2012 Sep; 47(2):430-43. PubMed ID: 22796217
[TBL] [Abstract][Full Text] [Related]
18. Formulation, characterization and tissue distribution of a novel pH-sensitive long-circulating liposome-based theranostic suitable for molecular imaging and drug delivery.
Duan Y; Wei L; Petryk J; Ruddy TD
Int J Nanomedicine; 2016; 11():5697-5708. PubMed ID: 27843312
[TBL] [Abstract][Full Text] [Related]
19. A novel approach for targeted delivery to motoneurons using cholera toxin-B modified protocells.
Gonzalez Porras MA; Durfee PN; Gregory AM; Sieck GC; Brinker CJ; Mantilla CB
J Neurosci Methods; 2016 Nov; 273():160-174. PubMed ID: 27641118
[TBL] [Abstract][Full Text] [Related]
20. Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord.
Dengler EC; Liu J; Kerwin A; Torres S; Olcott CM; Bowman BN; Armijo L; Gentry K; Wilkerson J; Wallace J; Jiang X; Carnes EC; Brinker CJ; Milligan ED
J Control Release; 2013 Jun; 168(2):209-24. PubMed ID: 23517784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
